Evidence map›Paper›PMID 41066034›Full record

Trial reportIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026

Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial.

Anudeep Katrevula, Rakesh Kalapala, Siddhant Agrawal, Nitin Jagtap, Pratik Chhabra, Anand V Kulkarni, Chandhana Merugu, Goutham Reddy Katukuri, Nageshwar Reddy Duvvur

Registry-linked trialAbstract readClinical Trial, Phase IVRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05442450. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05442450 phase4unknown status

Efficacy of Oral Semaglutide in Overweight or Obesity : Randomized Controlled Trial (OSO Study - Oral Semaglutide for Obesity)

Ran2022Enrolled116Registered outcomes8Posted comparisons0ConditionsObesity, Weight LossArmsOral semaglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anudeep KatrevulaDepartment of Medical Gastroenterology, AIG Hospitals, Hyderabad, 500 032, India.
Rakesh KalapalaDepartment of Medical Gastroenterology, AIG Hospitals, Hyderabad, 500 032, India. drkalpala@gmail.com.ORCID http://orcid.org/0000-0003-3203-7708
Siddhant AgrawalDepartment of Medical Gastroenterology, AIG Hospitals, Hyderabad, 500 032, India.
Nitin JagtapDepartment of Medical Gastroenterology, AIG Hospitals, Hyderabad, 500 032, India.
Pratik ChhabraDepartment of Medical Gastroenterology, AIG Hospitals, Hyderabad, 500 032, India.
Anand V KulkarniDepartment of Hepatology, AIG Hospitals, Hyderabad, 500 032, India.
Chandhana MeruguDepartment of Endocrinology, AIG Hospitals, Hyderabad, 500 032, India.
Goutham Reddy KatukuriDepartment of Medical Gastroenterology, AIG Hospitals, Hyderabad, 500 032, India.
Nageshwar Reddy DuvvurDepartment of Medical Gastroenterology, AIG Hospitals, Hyderabad, 500 032, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesObesity is a leading risk factor for fatty liver disease and weight loss has been shown to improve liver parameters. This study evaluates the efficacy of oral semaglutide for weight loss in individuals with overweight or obesity, excluding those with diabetes mellitus.

methodsA randomized, open-label, controlled trial was conducted at the Asian Institute of Gastroenterology, Hyderabad, from June 2022 to December 2023. Adults (≥ 18 years) with a body mass index (BMI) ≥ 30 or ≥ 27 with comorbidities (pre-diabetes, hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease) were randomized into two groups. Both groups received counselling on a reduced-calorie diet and increased physical activity. Group 1 also received oral semaglutide, starting at 3 mg/day and titrated to 14 mg/day over two to four weeks. The objectives were to assess the effects of semaglutide on weight loss, non-invasive markers of liver fibrosis and cardiometabolic parameters. (ClinicalTrials.gov ID: NCT05442450).

resultsTotal 116 participants (58 per group) completed the study. At 28 weeks, the mean percentage weight reduction was -10.47% (SD 5.3) in the Semaglutide group vs. -2.4% (SD 4.5) in the control group (p < 0.001). Semaglutide treatment significantly improved alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) levels, along with reductions in the aspartate aminotransferase to platelet ratio index (APRI) score, liver fat content and liver stiffness. However, NFS (NAFLD fibrosis score) and FIB-4 (fibrosis-4 index) did not show significant reductions. Improvements in BMI, waist circumference, HbA1c, fasting insulin and C-reactive protein (CRP) were significantly greater with semaglutide (p < 0.001). Total fat mass decreased by 7.3 kg vs. 1.74 kg (p < 0.0001) in controls, while visceral fat ratings dropped by 3.67 vs. 0.6 (p < 0.0001).

conclusionsIn adults with overweight or obesity without diabetes, oral semaglutide, combined with dietary and lifestyle modifications, led to significant and clinically meaningful weight loss and metabolic improvements compared to lifestyle modifications alone.

Indexed as

Glucagon-Like PeptidesLiver CirrhosisObesityOverweightWeight LossAdministration, OralAdultDiet, ReducingFemaleHumansMaleMiddle AgedSemaglutideTreatment OutcomeGlucagon-Like PeptidesSemaglutideFatty liverObesityOverweightSemaglutideWeight Loss

Identifiers

PMID41066034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.